In a new study, acute heart failure patients who received individualized treatment by blood volume measurement with the BVA-100 blood volume analyzer showed statistically significantly reduced 30-day readmission and 30-day and one-year mortality rates. The study, published in the Journal of the American College of Cardiology - Heart Failure,1 compared the experimental group to propensity-matched controls.

Fujifilm SonoSite Inc. announced the launch of its redesigned SonoSite Institute, a comprehensive online educational resource dedicated to empowering and educating healthcare providers about point-of-care ultrasound (POCUS). Based on the feedback of current global users, the enhanced website now features an improved user experience, easier-to-locate content and reconfigured learning paths.

November 1, 2018 — Daxor Corp. has entered an agreement with CHF Solutions to explore clinical synergies between Daxor’s ...

Amgen announced a new Repatha cardiovascular outcomes study (FOURIER) analysis evaluating the effects of Repatha (evolocumab) in patients with established cardiovascular disease by kidney function. In line with previous FOURIER subgroup analyses, these results further demonstrate Repatha's efficacy in reducing not only low-density lipoprotein cholesterol (LDL-C) levels, but also the relative risk for major cardiovascular events such as heart attack and stroke, in high-risk patients including those with mild-to-moderate chronic kidney disease (CKD).1-4 In these patients (N=4,443), absolute reductions tended to be greater in the risk for the composite secondary endpoint which included cardiovascular death, heart attack or stroke. Adverse events were similar across patients regardless of CKD stage and consistent with the Repatha known safety profile.